Casma Therapeutics Announces CEO Transition
Casma Therapeutics Raises $46.0 M in Series C Funding
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced that Keith...
CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to design innovative new medicines, today announced that Casma...
Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Keith Dionne, Ph.D., Chief Executive Officer of Casma, will participate in the upcoming virtual UBS Virtual Biotechnology Private Company Symposium being held on September 22-23, 2021.
Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced the appointment of Sharon Tooze, Ph.D. to its scientific advisory board (SAB).
CAMBRIDGE, Mass. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Casma Therapeutics, Inc. and Vipergen ApS announced today the signing of a drug discovery agreement. Under the terms of the agreement, Vipergen will apply its proprietary high-fidelity DNA-encoded library (DEL) technology platform to discover novel small-molecule drug leads against a broad range of undisclosed Casma discovery targets. Casma will retain exclusive rights to globally commercialize any products resulting from the collaboration. Financial details of the agreement were not disclosed.